HC Wainwright Reduces Earnings Estimates for Disc Medicine

Disc Medicine, Inc. (NASDAQ:IRON) – Investment analysts at HC Wainwright lowered their Q1 2026 EPS estimates for Disc Medicine in a research note issued on Tuesday, February 17th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($1.63) per share for the quarter, down from their previous forecast of ($1.56). The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. HC Wainwright also issued estimates for Disc Medicine’s Q2 2026 earnings at ($1.67) EPS, Q3 2026 earnings at ($1.74) EPS, Q4 2026 earnings at ($1.83) EPS, FY2026 earnings at ($6.88) EPS, FY2027 earnings at ($6.83) EPS, FY2028 earnings at ($5.27) EPS, FY2029 earnings at $0.57 EPS and FY2030 earnings at $7.08 EPS.

Several other equities analysts have also commented on IRON. Raymond James Financial reiterated a “market perform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. BMO Capital Markets lowered their price target on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating for the company in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research report on Wednesday, January 21st. Wedbush reduced their price objective on Disc Medicine from $110.00 to $88.00 and set an “outperform” rating on the stock in a research note on Tuesday. Finally, Morgan Stanley set a $75.00 price objective on Disc Medicine in a research report on Tuesday. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.82.

Disc Medicine Trading Down 1.8%

Shares of Disc Medicine stock opened at $63.35 on Thursday. Disc Medicine has a twelve month low of $30.82 and a twelve month high of $99.50. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05. The business has a 50-day moving average price of $77.24 and a 200-day moving average price of $75.12. The firm has a market cap of $2.39 billion, a price-to-earnings ratio of -11.84 and a beta of 0.88.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, COO Jonathan Yen-Wen Yu sold 3,231 shares of Disc Medicine stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total value of $203,100.66. Following the transaction, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at approximately $3,414,806.64. The trade was a 5.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Pamela Stephenson sold 5,531 shares of Disc Medicine stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total value of $347,678.66. Following the sale, the insider directly owned 80,998 shares of the company’s stock, valued at approximately $5,091,534.28. This represents a 6.39% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 284,761 shares of company stock valued at $24,913,484. 3.64% of the stock is currently owned by corporate insiders.

Institutional Trading of Disc Medicine

A number of hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Disc Medicine by 22.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock valued at $756,000 after purchasing an additional 2,807 shares during the period. Millennium Management LLC increased its holdings in Disc Medicine by 1,277.1% in the 1st quarter. Millennium Management LLC now owns 108,499 shares of the company’s stock worth $5,386,000 after acquiring an additional 100,620 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Disc Medicine by 3.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company’s stock worth $4,793,000 after acquiring an additional 3,454 shares in the last quarter. CWM LLC raised its position in Disc Medicine by 213.5% during the second quarter. CWM LLC now owns 1,044 shares of the company’s stock worth $55,000 after acquiring an additional 711 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new position in Disc Medicine during the second quarter valued at $497,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

More Disc Medicine News

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Management said it will pursue a traditional U.S. approval pathway for lead drug bitopertin after the FDA declined a fast‑track route, giving investors a clearer regulatory path rather than abandoning the program. Disc Medicine eyes standard US approval for drug after FDA denies fast-track nod
• Positive Sentiment: Several sell‑side firms (Cantor Fitzgerald, Stifel) have maintained constructive ratings (buy/overweight) even as some trimmed targets, which can support institutional interest and limit downside. Disc Medicine (IRON) Receives a Buy from Cantor Fitzgerald Stifel Nicolaus Sticks to Its Buy Rating for Disc Medicine (IRON)
• Neutral Sentiment: Market commentary and valuation checks are active as investors parse the FDA Complete Response Letter and implications for timing — some outlets ran valuation pieces and transcripts of the company investor call. Disc Medicine (IRON) Valuation Check After FDA Complete Response Letter On Lead Bitopertin Program
• Neutral Sentiment: Reported short‑interest prints are noisy/insignificant in the latest data, so today’s move looks driven largely by event‑driven trading and position rebalancing rather than a classic short‑squeeze dynamic.
• Negative Sentiment: Pomerantz LLP launched an investor investigation into Disc Medicine, introducing potential litigation risk and adding headline pressure that can deter buyers. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
• Negative Sentiment: Multiple insiders sold sizable blocks this week (CEO, CFO, COO and others), which investors often interpret as negative signal about near‑term outlook even though insiders still hold meaningful equity. John Quisel Sells 13,264 Shares of Disc Medicine (NASDAQ:IRON) Stock
• Negative Sentiment: HC Wainwright and other firms cut near‑ and long‑term EPS forecasts and several shops trimmed price targets, lowering the near‑term valuation baseline until regulatory clarity and data timelines are resolved.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.